What is the dosing range for CagriSema?

CagriSema is typically dosed at 0.25mg (low), 1.7mg (moderate), or 2.4mg (high) mg, administered once weekly subcutaneous (each component 2.4mg at target). These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of CagriSema?

Reported side effects of CagriSema include: Nausea (most common, dose-dependent), Vomiting, Diarrhea or constipation, Decreased appetite, Injection site reactions.

GLP-1

CagriSema

Also known as: Cagrilintide + Semaglutide, AM833 + semaglutide, amylin/GLP-1 combination

Share:Share on Reddit

Reviewed by the Research Stack Editorial TeamLast reviewed August 3, 20262 peer-reviewed sources

CagriSema is an investigational combination and is NOT FDA-approved. Efficacy figures are from sponsor trials and conference reports. This is not the same as separately-sourced cagrilintide or semaglutide. For research and educational purposes only — not medical advice.

📚 Content aggregated from:2 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study.

Research Summary

CagriSema combines amylin-receptor agonism (cagrilintide — satiety and gastric emptying via the area postrema/hypothalamus) with GLP-1 agonism (semaglutide), two non-overlapping appetite mechanisms. The REDEFINE 1 and 2 trials supported a December 2025 FDA filing for weight management. However, the open-label REDEFINE-4 head-to-head trial showed 23.0% weight loss vs 25.5% for tirzepatide 15 mg, missing its primary non-inferiority endpoint. An FDA decision is expected in late 2026.

Dosing Range

low

0.25mg

moderate

1.7mg

high

2.4mg

Units: mg · Frequency: once weekly subcutaneous (each component 2.4mg at target)

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injection (weekly)

Reconstitution Notes

CagriSema is a fixed-dose combination delivered via a single prefilled pen in clinical trials. It is investigational — no pharmaceutical-grade product is publicly available, and it should not be confused with separately-sourced cagrilintide or semaglutide.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Nausea (most common, dose-dependent)
Vomiting
Diarrhea or constipation
Decreased appetite
Injection site reactions

Research Papers

2 peer-reviewed sources

REDEFINE-4: CagriSema misses non-inferiority vs tirzepatide (head-to-head)

HCPLive (trial coverage)2026

Novo Nordisk CagriSema REDEFINE program announcement

Novo Nordisk (investor relations)2026

Latest CagriSema Research

Most recent publications from PubMed, refreshed daily. Automatically retrieved — not editorially curated.

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/Semaglutide

Community discussion comparing CagriSema's amylin+GLP-1 approach to tirzepatide and semaglutide alone.

View original thread

Overview

CagriSema is an investigational once-weekly combination from Novo Nordisk that pairs two peptides in a single injection:

Cagrilintide — a long-acting amylin analog (see the cagrilintide profile)
Semaglutide — the GLP-1 receptor agonist behind Ozempic and Wegovy (see the semaglutide profile)

The idea is mechanistic complementarity: amylin and GLP-1 suppress appetite through different, non-overlapping pathways, so combining them can push weight loss higher than either alone without simply stacking GI side effects.

Mechanism

Amylin (cagrilintide) — activates amylin receptors in the area postrema and hypothalamus, promoting satiety and slowing gastric emptying, independent of GLP-1
GLP-1 (semaglutide) — reduces appetite via central pathways, slows gastric emptying, and improves glucose-dependent insulin secretion

Because the two act on separate satiety circuits, the combination targets appetite more completely than a single mechanism.

Clinical Data — Promising, but with an Important Caveat

REDEFINE 1 & 2 supported CagriSema's efficacy in obesity and underpinned Novo Nordisk's December 2025 FDA filing for weight management, with weight loss in the ~20% range.

But the head-to-head result matters. In the open-label REDEFINE-4 trial comparing CagriSema directly against tirzepatide, CagriSema produced 23.0% weight loss versus 25.5% for tirzepatide 15 mg — missing its primary non-inferiority endpoint. In other words, in a direct comparison, CagriSema did not prove itself at least as good as tirzepatide. This is an honest and important nuance often glossed over: CagriSema is highly effective, but the current data do not show it beating the leading approved dual agonist.

Status

CagriSema is investigational and not FDA-approved. Novo filed for weight management in December 2025 (based on REDEFINE 1 and 2), with an FDA decision expected in late 2026. Because it is investigational, it should not be confused with — or substituted by — separately-sourced cagrilintide and semaglutide combined outside a trial.

How It Compares

| Agent | Mechanism | Reported weight loss | |---|---|---| | Semaglutide | GLP-1 | ~15% | | CagriSema | Amylin + GLP-1 | ~20–23% | | Tirzepatide | GIP + GLP-1 | ~21–25.5% | | Retatrutide (investigational) | GIP + GLP-1 + glucagon | ~24–30% |

CagriSema sits firmly in the high-efficacy tier — but the REDEFINE-4 miss suggests the amylin+GLP-1 route, while excellent, may not out-perform the incretin dual/triple agonists on weight loss alone.